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TRILOSTANE IN DOGS 
 
 
N. Sieber-Ruckstuhl 
 
 
 
Trilostane 
Trilostane is a synthetic steroid analogue that inhibits the enzyme 3β-
hydroxysteroid dehydrogenase (3β-HSD). The 3β-HSD is essential for the 
biosynthesis of all classes of steroid hormones, namely glucocorticoids, 
mineralocorticoids, progesterone, androgens and estrogens. Trilostane (Vetoryl®) is 
approved for treatment of canine hyperadrenocorticism (HAC). 
 
 
1. Starting dose and frequency 
When trilostane was introduced on the veterinary market the recommended 
staring dose was 2-10 mg/kg once daily. Nowadays, however, frequent users agree 
on much lower doses. We recommend a starting dose of 1-2 mg/kg once daily. 
Larger dogs (> 15 kg) need lower doses and should therefore be started on 1 mg/kg 
once daily.1 
 
It is well known that the effect of trilostane does not last for 24h. Whether once- or 
twice-daily administration is better is unclear. We usually start dogs on once daily 
therapy. After 10-12 weeks we evaluate the dogs with a special focus on the clinical 
signs during the late afternoon and at night. If the suspicion arises that the effect of 
trilostane is too short, an ACTH stimulation test 24h after the last dosing is 
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performed. If the test confirms that activity is too short, the dog is changed to twice 
daily therapy. Dogs with concurrent diseases influenced by high cortisol levels (e.g. 
diabetes mellitus) as well as cats are started on 0.5-1 mg/kg twice daily. 
 
Trilostane absorption is increased by food. Therefore, we tell our owners to 
administer trilostane with food. 
 
 
2. Timing of dose adjustments 
Regardless of the starting dose, dose adjustments, either up or down, will be 
required during the course of treatment.2-4 The first recheck should be approximately 
after 10-14 days. However, the dose should only be changed if either the post-ACTH 
cortisol concentration is below ideal or if no clinical improvement has been noted and 
the post-ACTH cortisol concentration is still much higher than ideal. Cortisol 
concentrations decrease until 4 weeks after treatment start, even if the dog remains 
on the same dose. Further rechecks are recommended after about 4, 8, 12 and 16 
weeks and thereafter about every 3-6 months. In general, many dogs need initial 
dose increases and later during long-term therapy, dose decreases.  
 
 
3. Timing of monitoring 
The treatment is monitored by regular ACTH-stimulation tests. The timing of post-
pill sampling is most important. It is well known that post-ACTH cortisol varies 
depending on the interval between dosing and testing. Therefore, it is important to 
keep the interval constant for each patient from test to test. We perform the ACTH 
stimulation test 2-3 hours post-pill and use a reference range of 2-5 ug/dl (55-135 
nmol/l) for the post-ACTH cortisol. The same treatment goals are used for dogs on 
twice daily therapy.  
 
 
4. Efficacy 
In the majority of patients trilostane is highly effective in suppressing cortisol 
secretion and controlling clinical signs. Many clinical signs (e.g. decreased activity, 
polyuria and polydipsia) resolve quickly, but certain ones (e.g. dermatological 
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abnormalities, pendulous abdomen) can take several months to improve.2-4 A small 
proportion of dogs with pituitary-dependent HAC are not well controlled with 
trilostane. 
 
In dogs with concurrent diabetes mellitus we prefer to start trilostane twice daily to 
more consistently decrease the cortisol levels. Insulin requirements and fructosamine 
concentrations do not consistently decrease during trilostane treatment.5 
Furthermore, prospective reduction in insulin doses at the start of trilostane treatment 
is probably not warranted.   
 
Trilostane does work in adrenal-dependent HAC. Comparison of the median 
survival times between mitotane and trilostane treated dogs with adrenal-dependent 
HAC revealed no significant difference.6 Although the studies have limitations and the 
numbers of dogs included were small, it seems that the use of mitotane in adrenal 
dependent HAC does not confer a major clinical advantage.   
 
 
5. Safety 
Adverse effects of trilostane are usually mild and self-limiting and most often 
include lethargy and vomiting.2-4 Excess adrenal gland suppression, however, can 
occur and warrants immediate discontinuation of trilostane therapy. As trilostane is a 
competitive enzyme inhibitor, its effect should be rapidly reversible. However, in 
some cases adrenal suppression can last weeks to years. In these cases adrenal 
necrosis may be suspected, possibly induced by the elevated ACTH concentrations 
during therapy.7,8 With oversuppression, we recommend discontinuing trilostane 
therapy, administering a few days of prednisolone if dogs show clinical signs of 
adrenal insufficiency and waiting with the re-starting trilostane therapy until the 
clinical signs of HAC return. Before re-start of trilostane therapy, we prefer to perform 
an ACTH stimulation test to document adrenal restoration. Trilostane should then be 
re-introduced at a very low dose (0.1-0.5 mg/kg) and increased very slowly.  
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